SI-BONE FY2024 EPS Forecast Increased by Cantor Fitzgerald

SI-BONE, Inc. (NASDAQ:SIBN - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for shares of SI-BONE in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($0.65) for the year, up from their prior estimate of ($0.69). The consensus estimate for SI-BONE's current full-year earnings is ($0.78) per share. Cantor Fitzgerald also issued estimates for SI-BONE's FY2025 earnings at ($0.19) EPS.

A number of other research firms also recently issued reports on SIBN. Truist Financial boosted their target price on shares of SI-BONE from $16.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Needham & Company LLC reissued a "buy" rating and set a $19.00 price objective on shares of SI-BONE in a research report on Monday, January 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $23.00.

SI-BONE Trading Down 2.4 %

SIBN traded down $0.39 during trading on Thursday, hitting $16.25. The company's stock had a trading volume of 148,293 shares, compared to its average volume of 332,965. The firm has a market capitalization of $681.36 million, a P/E ratio of -17.66 and a beta of 1.16. SI-BONE has a twelve month low of $11.70 and a twelve month high of $21.64. The stock's fifty day moving average price is $13.93 and its 200-day moving average price is $14.41. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

Institutional Investors Weigh In On SI-BONE

A number of institutional investors have recently added to or reduced their stakes in the company. FMR LLC boosted its stake in shares of SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after buying an additional 1,198 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in SI-BONE during the second quarter worth $61,000. R Squared Ltd purchased a new position in SI-BONE in the fourth quarter worth $73,000. Walleye Capital LLC bought a new position in SI-BONE in the 3rd quarter valued at $144,000. Finally, Deerfield Management Company L.P. Series C purchased a new stake in shares of SI-BONE during the 2nd quarter valued at $151,000. 98.11% of the stock is owned by institutional investors.

Insider Buying and Selling at SI-BONE

In other SI-BONE news, CEO Laura Francis sold 10,048 shares of the firm's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the transaction, the chief executive officer now directly owns 482,875 shares in the company, valued at approximately $6,074,567.50. This trade represents a 2.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anthony J. Recupero sold 3,937 shares of the company's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.60, for a total transaction of $49,606.20. Following the completion of the sale, the insider now owns 228,554 shares of the company's stock, valued at approximately $2,879,780.40. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,348 shares of company stock valued at $356,349. Corporate insiders own 3.90% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.